Intellia Therapeutics (NTLA) Reports In-Line Q2 EPS
Tweet
Share
E-mail
Get Alerts NTLA Hot Sheet
Join SI Premium – FREE
Intellia Therapeutics (NASDAQ: NTLA) reported Q2 EPS of ($0.80), in-line with the analyst estimate of ($0.80). Revenue for the quarter came in at $7.66 million versus the consensus estimate of $13.18 million.
For earnings history and earnings-related data on Intellia Therapeutics (NTLA) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Oracle (ORCL) PT Lowered to $290 at Jefferies
- Rothschild Redburn Starts Mettler-Toledo (MTD) at Sell
- Dell Technologies (DELL) Tops Q2 EPS by $2.17, Offers Guidance
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
